Research programme: SARS-CoV-2 neutralising monoclonal antibodies - International AIDS Vaccine Initiative/The Scripps Research Institute/Serum Institute of India/Merck
Alternative Names: COVID-19 monoclonal antibodies - Merck/Serum Institute of IndiaLatest Information Update: 09 Nov 2020
At a glance
- Originator International AIDS Vaccine Initiative; The Scripps Research Institute
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 22 Oct 2020 International AIDS Vaccine Initiative and Serum Institute of India enters into an agreement with Merck to develop SARS-CoV-2 neutralizing monoclonal antibodies
- 22 Oct 2020 Early research in COVID-2019 infections in USA (Parenteral)
- 22 Oct 2020 Merck and Serum Institute plans a phase I trial for COVID-2019 infections in early 2021